|Aggregate principal amount, description
||In addition, the Seller agreed that the Seller Loans may include
additional amounts to cover certain costs and expenses that Legacy will reasonably incur in connection with the continuation of
operations until the earlier of the consummation of the Business Combination or the Extended Date and the total of all such costs
and expenses shall not exceed a total of $300,000 in the aggregate for all Extensions through the Extended Date. No Seller Loan
may exceed $1,000,000 in the aggregate (including loans to fund costs and expenses). The Seller Loans made on or about October
23, 2019, December 21, 2019 and January 21, 2020,, each in the principal amount of approximately $979,000 under the Amended Seller
Note reflects a loan to fund the Company’s Contributions to the Trust Account of approximately $879,000 plus $100,000 to
fund the costs and expenses that the Company reasonably expects incur in connection with the continuation of operations until
the earlier of the consummation of the Business Combination or the Extended Date. As of January 21, 2020, Legacy had borrowed
in respect of its costs and expenses a total of $300,000 in the aggregate.
||the Company issued a note (the “Seller
Note”) for the aggregate principal amount of approximately $979,000, to the Seller (including $100,000 provided to the Company
for working capital). Borrowings under the Seller Note will bear interest at a rate equal to the 1-month USD LIBOR interest rate,
plus 1.5%. The Seller Note was issued in connection with the approval by the Company’s stockholders of the Extension Amendment.
In connection with the Extension Amendment, stockholders elected to redeem 694,820 shares of the Company’s Class A common
stock, par value $0.0001 per share, issued in the Company’s initial public offering (the “public shares”), and
29,305,180 public shares remain issued and outstanding following such redemptions. Accordingly, consistent with the Company’s
proxy materials relating to the special meeting, on or about October 23, 2019, the Company made a cash contribution to the Trust
Account in an amount equal to $0.03 for each public share that was not redeemed in connection with the stockholder approval of
the Extension Amendment for the initial extension through December 21, 2019, which equaled an aggregate amount of approximately
$979,000 (including $100,000 provided to Company for costs and expenses). On December 17, 2019, in connection with the Company’s
extension of the date by which the Company has to consummate a business combination from December 21, 2019, to January 21, 2020,
the Company issued an amended and restated note (the “Amended Seller Note”) to the Seller that amended and restated
the Seller Note and received the second Seller Loan from the Seller. Borrowings under the Amended Seller Note will continue to
bear interest at a rate equal to the 1 month USD LIBOR interest rate, plus 1.5% accruing from the date of the applicable borrowings.
Subsequent to December 31, 2019, the Company has extended the date by which it has to consummate a business combination from January 21, 2020 to February
20, 2020, and from February 20, 2020 to March 21, 2020. In connection with each of the first three extensions, the Seller loaned
$979,155.40 to the Company under the Amended Seller Note. Additionally, in connection with the fourth and most recent extension,
the Seller loaned $879,155.40. As a result, Seller will have loaned to the Company a total aggregate amount of $3,816,621.60.
|Business Combination, description
||In addition, the Company has (and will) make additional Contributions of $0.03 per outstanding public share for each period
of the extension by Legacy at its option and/or at the Seller’s request. The Seller has so far made Contributions of $979,155.40
for each of the first three extensions, and $879,155.40 for the fourth and most recent extension to March 21, 2020, for Contributions
of a total aggregate amount of $3,816,621.60. If the Company elects and/or the Seller requests that the Company extend the date
for either or both of the two remaining 30-day extension periods, the Seller would make Contributions of approximately $879,000,
respectively. If, however, the Seller does not request that we extend beyond March 21, 2020 or any additional 30-day period thereafter
and the Company also determines not to extend or our board of directors otherwise determines that the Company will not be able
to consummate an initial business combination by the Extended Date and does not wish to have an additional Extension, the Company’s
board of directors would wind up our affairs and redeem 100% of the outstanding public shares.